Literature DB >> 9075809

Hypertension as a risk factor for diabetic neuropathy: a prospective study.

K Y Forrest1, R E Maser, G Pambianco, D J Becker, T J Orchard.   

Abstract

The pathogeneses of diabetic neuropathy is still unclear. This study prospectively investigated the risk factors for distal symmetrical polyneuropathy (DSP) in a cohort of childhood-onset IDDM patients. Subjects from the Epidemiology of Diabetes Complications (EDC) Study were clinically examined at baseline and then biennially. DSP was diagnosed by a combination of clinical criteria, symptoms and signs (Diabetes Control and Complications Trial [DCCT] exam), and quantitative sensory threshold (QST). Among the 463 (70.4%) subjects who were free of DSP at baseline, 453 (97.8%) participated in at least one biennial reexamination during the first 6 years of follow-up and were included in the current analysis. A total of 68 (15.0%) subjects developed DSP in 6 years, giving a cumulative probability of 0.29. The Cox proportional hazards model shows that longer IDDM duration, hypertension, poor glycemic control, height, and smoking were all independent predictors of the incidence of DSP (all P < 0.0001, except for smoking for which P = 0.03). Hypertension showed the greatest impact on the development of DSP for individuals with either short or long IDDM duration. This study confirms some risk factors for DSP found in cross-sectional studies and suggests a strong relationship between hypertension and DSP. The results indicate that in addition to good glycemic control, avoidance of smoking and good blood pressure control may be helpful in preventing or delaying the onset of DSP in IDDM patients.

Entities:  

Mesh:

Year:  1997        PMID: 9075809     DOI: 10.2337/diab.46.4.665

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  50 in total

Review 1.  Role of ACE inhibitors in patients with diabetes mellitus.

Authors:  D J Cordonnier; P Zaoui; S Halimi
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Risk factors for diabetic neuropathy and foot ulceration.

Authors:  A Adler
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

Review 3.  Drug therapy for chronic idiopathic axonal polyneuropathy.

Authors:  Janna Warendorf; Alexander Fje Vrancken; Ivo N van Schaik; Richard Ac Hughes; Nicolette C Notermans
Journal:  Cochrane Database Syst Rev       Date:  2017-06-20

4.  Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus.

Authors:  D R Witte; S Tesfaye; N Chaturvedi; S E M Eaton; P Kempler; J H Fuller
Journal:  Diabetologia       Date:  2004-12-24       Impact factor: 10.122

Review 5.  The prevalence of diabetic neuropathy according to ethnicity.

Authors:  Jay M Sosenko
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

6.  Increased aortic stiffness predicts future development and progression of peripheral neuropathy in patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study.

Authors:  Claudia R L Cardoso; Camila B M Moran; Fernanda S Marinho; Marcel T Ferreira; Gil F Salles
Journal:  Diabetologia       Date:  2015-06-05       Impact factor: 10.122

Review 7.  Measurement of somatic neuropathy for clinical practice and clinical trials.

Authors:  L V Scott; S Tesfaye
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

8.  Long-term mortality in nationwide cohorts of childhood-onset type 1 diabetes in Japan and Finland.

Authors:  Keiko Asao; Cinzia Sarti; Tom Forsen; Valma Hyttinen; Rimei Nishimura; Masato Matsushima; Antti Reunanen; Jaakko Tuomilehto; Naoko Tajima
Journal:  Diabetes Care       Date:  2003-07       Impact factor: 19.112

Review 9.  The Eurodiab study: what has this taught us about diabetic peripheral neuropathy?

Authors:  Solomon Tesfaye; Dinesh Selvarajah
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

Review 10.  Mitigating micro-and macro-vascular complications of diabetes beginning in adolescence.

Authors:  Daniel J Moore; Justin M Gregory; Yaa A Kumah-Crystal; Jill H Simmons
Journal:  Vasc Health Risk Manag       Date:  2009-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.